GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro were initially developed to treat type 2 diabetes, but their effectiveness as anti-obesity medications has generated tremendous excitement and high demand among people who have struggled to lose weight by other means
Microdoses, however, usually come from compounding pharmacies, which formulate custom doses
Methods Data Source EHR and prescription data were extracted from the IBM Explorys EHR database (IBM Watson Health, Armonk, NY, USA), allowing clinical outcomes to be linked to treatment use
Between 20%-50% of weight lost on GLP-1 drugs is muscle loss
285,286,287 The MAPK pathway is an important pathway related to UC, 288 and its inhibition reduces inflammation by downregulating the levels of proinflammatory cytokines
Ectopic lymphoid structures: powerhouse of autoimmunity